| Grace N Olanrewaju, | |
|
7600 Georgia Ave Nw Ste 323, Washington, DC 20012-1616 | |
| (202) 723-3060 | |
| Not Available |
| Full Name | Grace N Olanrewaju |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 7600 Georgia Ave Nw Ste 323, Washington, District Of Columbia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376000299 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | LPN1004596 (District Of Columbia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Grace N Olanrewaju, 7600 Georgia Ave Nw Ste 323, Washington, DC 20012-1616 Ph: (202) 723-3060 | Grace N Olanrewaju, 7600 Georgia Ave Nw Ste 323, Washington, DC 20012-1616 Ph: (202) 723-3060 |
News Archive
According to the Guttmacher Institute, over ten million women in the US use oral contraceptives. Although birth control pills are an effective way to prevent pregnancy, keep acne at bay, and treat menstrual pain or irregularity, there may be some health concerns that are undisclosed to patients. A recent study suggests that oral contraceptive use can lead to increased pain during intercourse, with decreased libido and spontaneous arousability as well as diminished frequency of sexual intercourse and orgasm in young women.
Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today regarding appropriate incentives for continued biotechnology innovation:
Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).
The intestinal hormone secretin, considered by some to be a promising drug in the treatment of autism, does not improve the symptoms and should not be used to treat the disorder, according to a new review of studies.
"Fourteen cities and towns that have moved their employees, retirees, and elected officials from their own municipal-based health care insurance plans into the state's much larger, more flexible system collectively saved more than $30 million their first year in the program, according to a new report. … The study relies on self-reported fiscal data on the communities' first year in the Group Insurance Commission, the state health care program, which covers some 300,000 state employees, retirees, and elected officials" (Murphy, 8/3).
› Verified 5 days ago
Emmanuel Mbu, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2811 Pennsylvania Ave Se, Washington, DC 20020 Phone: 301-379-8449 | |
Stella Segun, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 6856 Eastern Ave Nw, Suite 220, Washington, DC 20012 Phone: 202-545-6980 | |
Yolanda Blagrove, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 801 Pennsylvania Ave Se, Washington, DC 20003 Phone: 202-796-0605 | |
Nwaneka Onuaku, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 6856 Eastern Ave Nw Ste 320a, Washington, DC 20012 Phone: 202-541-9844 | |
Priscillia N Moghalu, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 6856 Eastern Ave Nw, Washington, DC 20012 Phone: 202-541-9844 | |
Jasmine Rhodes, HHA, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 505 Madison St Nw, Washington, DC 20011 Phone: 202-600-6972 | |
Rochelle Fadare, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 7600 Georgia Ave Nw Ste 323, Washington, DC 20012 Phone: 202-723-3060 Fax: 202-723-3065 |